Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

even during cancer treatment. Scientists also revealed that circular fragments of DNA called extrachromosomal DNA (ecDNA) is ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free ...

There are 3 main ways that hormone therapy is used to treat patients with hormone-sensitive breast cancer: neoadjuvant therapy, adjuvant therapy, and treatment of patients with metastatic breast ...

BMI's Relation to Cancer Therapy Mortality Risks Not So Straightforward ... 2024 — Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy -- given ...

Pertuzumab (Perjeta) treats HER2-positive early breast cancer, usually in combination with trastuzumab and chemotherapy. It’s FDA-approved for neoadjuvant and adjuvant treatment. Neoadjuvant use ...